Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GERMINATE: Immune Responses to LAIV vs Influenza A Challenge in Healthy Volunteers
NCT06620185Recruiting
- Sponsor
- Imperial College London
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of live attenuated influenza vaccine in influenza (2 arms), sponsored by Imperial College London. Primary endpoints: Peak symptoms related to inoculation at 14 days, Average duration of symptoms related to inoculation at 14 days and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06620185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620185.